BARDA urged to share potential Ebola treatment with global outbreak response

17 June 2026

Public Citizen, Health Global Access Project, and eight organizations sent a letter to the US Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services urging the US government to share candidate Ebola Bundibugyo therapeutics that it has in its possession and coordinate with the World Health Organization, Africa CDC, affected-country governments, medical humanitarian organizations and international and civil society to address current and future outbreaks.

The current Ebola Bundibugyo outbreak is caused by a less common strain of Ebola, for which there are no approved therapeutics, vaccines, or rapid tests. There are, however, promising candidate treatments that the World Health Organization has recommended for testing in emergency clinical trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical